Ultrasound-targeted microbubbles for treating lung cancer and preparation method and application thereof
By designing ultrasound-targeted microbubbles and using streptavidin and biotin systems to link bevacizumab, drug penetration is enhanced, solving the problems of insufficient targeting and poor penetration in lung cancer treatment, and achieving highly efficient treatment of lung cancer.
Patent Information
- Application Number
- CN202610599238.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-30
- Publication Date
- 2026-07-17
AI Technical Summary
Existing drugs for treating lung cancer suffer from problems such as insufficient targeting, high risk of side effects due to systemic distribution, and difficulty in penetrating tumor tissues, especially for non-small cell lung cancer (NSCLC). There are currently no targeted microbubbles suitable for ultrasound therapy.
An ultrasound-targeted microbubble was designed with streptavidin attached to its outer surface, loaded with biotinylated bevacizumab, and containing perfluorinated carbon gas inside. The microbubble is connected via a streptavidin-biotin system to form a monolayer membrane structure, which is used to enhance drug penetration and therapeutic efficacy.
It significantly enhanced drug penetration into lung cancer tissue, reduced systemic side effects, significantly inhibited tumor growth and angiogenesis, and enhanced the anticancer effect of bevacizumab.
Smart Images
Figure CN122399054A_ABST